Numans Health Food Holdings Company Limited
HHKEX:25300.72
HKD
+0.03
(+3.62%)
ISIN
KYG6781U1085
CUSIP
G6781U108
Return %
Stock
S&P 500
1Y
19.17
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Ping Wang
- Full Time Employees
- 50
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Building 8 Lane 706 Shanghai GD China
- IPO Date
- Jan 10, 2025
- Website
- numans.cc
- Similar Companies
- Business
- Numans Health Food Holdings Company Limited (2530.HK) is an investment holding company principally engaged in the marketing, sales, and distribution of finished nutritional products in the People's Republic of China. The company offers algal oil docosahexaenoic acid (DHA), probiotics, vitamins, multi-nutrients, algal calcium, and milk powder products under its proprietary brands "Nemans," "紐曼思," and "紐曼斯," targeting consumers ranging from pregnant and postpartum women to infants and children; it distributes these products through online channels, including direct sales to e-commerce companies and online shopping platforms, and offline channels such as regional distributors and retail outlets, while also importing raw materials. Founded in 2002 and headquartered at Building 8, Lane 706, Wuxing Road, Pudong New Area, Shanghai, China, the company operates as a subsidiary of Far-East Fortune Management (China) Co., Ltd., with its principal place of business in Hong Kong and all revenue derived from the PRC market. In a major development, Numans successfully completes its initial public offering and lists its shares on the Main Board of The Stock Exchange of Hong Kong on January 10, 2025, raising net proceeds of approximately HK$124.0 million to support expanded marketing efforts, brand awareness, and sales network growth amid a challenging year where revenue declines 34.9% to RMB277.5 million due to post-stockpiling demand normalization and economic pressures, yet maintains a gross profit margin of 76.1%; the board subsequently recommends a final dividend of RMB5.00 cents per share for 2024.